Patents Assigned to Chinese Academy of Medical Sciences
-
Publication number: 20160089390Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.Type: ApplicationFiled: January 26, 2014Publication date: March 31, 2016Applicant: Institute of Medicinal Biotechnology, Chinese Academy of Medical SciencesInventors: Bin HONG, Li WANG, Xiaojian JIA, Huajun JIANG, Yu DU, Fan YANG, Shuyi SI
-
Patent number: 9266897Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.Type: GrantFiled: October 24, 2012Date of Patent: February 23, 2016Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
-
Patent number: 9226496Abstract: Disclosed is a biomimetic adhesive belonging to prevention and treatment of plant pest. The components and ratio of raw materials thereof are as follows: 25-50% of soft acrylic monomer, 1-5% of acrylic monomer, 0.1-0.3% of nonionic emulsifier, 0.1-0.8% of anionic emulsifier, 0.2-0.6% of catalyst, 0.1-0.3% of antiseptic, 0.02-0.05% of defoamer, and deionized water as remainder. Fluorescent substances or insect pheromones can also be added to said biomimetic adhesive. The biomimetic adhesive of the present invention has good effect of insect sticking without environmental impact, has long time effect, is safe, non-toxic and non-polluting, and can be sprayed directly onto the surface of plant branch and leaves using an ordinary sprayer due to its low viscosity at room temperature. It also has no adverse effects on photosynthesis and normal growth of plants. The preparation method of the biomimetic adhesive is also disclosed.Type: GrantFiled: November 29, 2010Date of Patent: January 5, 2016Assignees: Institute of Medicinal Plant Development The Chinese Academy of Medical Sciences, Foshan Sanshui Xianghai Adhesive Co., Ltd.Inventors: Changqing Xu, Jun Chen, Liuying Yu
-
Patent number: 9206405Abstract: A novel glycosyl hydrolase with activities of beta-xylosidase and beta-glucosidase is provided. Said glycosyl hydrolase can convert 7-xylosyltaxane compounds to 7-hydroxyltaxane compounds.Type: GrantFiled: April 12, 2011Date of Patent: December 8, 2015Assignee: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Ping Zhu, Haili Cheng, Ruiyu Zhao, Kedi Cheng, Huixia He, Chao Meng, Huixin Zhu
-
Patent number: 9066960Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.Type: GrantFiled: August 22, 2007Date of Patent: June 30, 2015Assignee: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yuling Liu, Zhufang Shen, Zhen Chen, Renyun Wang, Xuejun Xia, Yueteng Chen, Quan Liu, Sujuan Sun, Mingzhi Xie
-
Publication number: 20150031717Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.Type: ApplicationFiled: October 24, 2012Publication date: January 29, 2015Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Hailin Qin, Wenjie Wang, Zhihui Zhang, Lianqiu Wu, Anjun Deng, Jinqian Yu, Zhihong Li
-
Publication number: 20140323501Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.Type: ApplicationFiled: July 5, 2012Publication date: October 30, 2014Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
-
Patent number: 8790663Abstract: Provided are antigenic determinants of human death receptor DR5. The antigenic determinants have the amino acid sequence of LITQQDLAPQQRA (SEQ ID No. 7), wherein the core polypeptide is QDLAP (SEQ ID No. 1). The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine.Type: GrantFiled: April 3, 2009Date of Patent: July 29, 2014Assignee: Institute of Basic Medical Sciences, Chinese Academy of Medical SciencesInventors: Yanxin Liu, Peng Zhang, Yong Zheng, Dexian Zheng
-
Publication number: 20140186286Abstract: Disclosed is a biomimetic adhesive belonging to prevention and treatment of plant pest. The components and ratio of raw materials thereof are as follows: 25-50% of soft acrylic monomer, 1-5% of acrylic monomer, 0.1-0.3% of nonionic emulsifier, 0.1-0.8% of anionic emulsifier, 0.2-0.6% of catalyst, 0.1-0.3% of antiseptic, 0.02-0.05% of defoamer, and deionized water as remainder. Fluorescent substances or insect pheromones can also be added to said biomimetic adhesive. The biomimetic adhesive of the present invention has good effect of insect sticking without environmental impact, has long time effect, is safe, non-toxic and non-polluting, and can be sprayed directly onto the surface of plant branch and leaves using an ordinary sprayer due to its low viscosity at room temperature. It also has no adverse effects on photosynthesis and normal growth of plants. The preparation method of the biomimetic adhesive is also disclosed.Type: ApplicationFiled: November 29, 2010Publication date: July 3, 2014Applicants: Foshan Sanshui Xianghai Adhesive Co., Ltd., Institute of Medicinal Plant Development, The Chinese Academy of Medical SciencesInventors: Changqing Xu, Jun Chen, Liuying Yu
-
Patent number: 8765695Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.Type: GrantFiled: December 25, 2007Date of Patent: July 1, 2014Assignees: Jecui Health Industry Corp. Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Juntian Zhang, Shifeng Chu
-
Patent number: 8735561Abstract: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.Type: GrantFiled: September 18, 2007Date of Patent: May 27, 2014Assignee: Chinese Academy of Medical Sciences, Institute of Basic Medical SciencesInventors: Xuemei Xu, Ting Zhang, Yufei Xu, Dongsheng Fan
-
Patent number: 8729280Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.Type: GrantFiled: November 28, 2009Date of Patent: May 20, 2014Assignee: Institute of Mataria Medica, Chinese Academy of Medical SciencesInventors: Yang Lv, Xiaoguang Chen, Ping Xie, Li Zhang, Cheng Wang
-
Patent number: 8722030Abstract: The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single sodium ferulate adjuvant and single zinc hydroxide adjuvant. It is not only atoxic, safety, but also reliable in the range of immune dose. The composite vaccine adjuvant with easily obtained and commercially available raw materials, is low cost, stable performance and simple preparation technology, which can be used as an adjuvant of hepatitis B vaccine, gene-engineered vaccine, virus vaccine and so on.Type: GrantFiled: March 22, 2011Date of Patent: May 13, 2014Assignee: Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInventors: Yunzhang Hu, Ningzhu Hu, Haixuan Wang
-
Patent number: 8710098Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.Type: GrantFiled: September 28, 2009Date of Patent: April 29, 2014Assignee: Institute of Medicinal Biotechnology Chinese Academy of Medical ScienceInventors: Jian-Dong Jiang, Liyan Yu, Shan Cen, Zhuorong Li, Yanping Li, Jian Xu
-
Patent number: 8709779Abstract: The characterization of a new strain of human rhinovirus of genetic group C (HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided.Type: GrantFiled: April 16, 2009Date of Patent: April 29, 2014Assignees: Biomerieux, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing Children's Hospital Affiliated to Capital Medical UniversityInventors: Richard Gonzalez, Jianwei Wang, Zichun Xiang, Kunling Shen
-
Publication number: 20130338064Abstract: Provided are an insulin-lipid complex, a preparation method thereof, and a formulation thereof. The insulin-lipid complex is prepared by compounding insulin and a lipid material in an organic solvent system containing a low boiling point acid, and drying. The mass ratio of insulin to the lipid material is 1:3˜1:20. An oil solution of the insulin-lipid complex and vesicles containing insulin are further provided.Type: ApplicationFiled: July 14, 2011Publication date: December 19, 2013Applicant: Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Yuling Liu, Cuiping Zhou, Zhihui Song, Lin Li, Hongliang Wang, Xuejun Xia, Renyun Wang, Wujun Dong, Dujia Jin
-
Patent number: 8524744Abstract: Disclosed Arylamine ketones of formula (I), their preparation methods, the pharmaceutical compositions containing them and their use in preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc.Type: GrantFiled: August 5, 2005Date of Patent: September 3, 2013Assignee: Institute of Mataria Medica, Chinese Academy of Medical SciencesInventors: Liya Zhu, Wenjie Wang, Halhong Huang, Ziyun Lin, Liyuan Mou, Zhengui Nie, Yu He, Xueyu Ouyang, Shanying Peng, Dongfong Zhang, Jun Wei
-
Publication number: 20130202651Abstract: The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single sodium ferulate adjuvant and single zinc hydroxide adjuvant. It is not only atoxic, safety, but also reliable in the range of immune dose. The composite vaccine adjuvant with easily obtained and commercially available raw materials, is low cost, stable performance and simple preparation technology, which can be used as an adjuvant of hepatitis B vaccine, gene-engineered vaccine, virus vaccine and so on.Type: ApplicationFiled: March 22, 2011Publication date: August 8, 2013Applicant: INSTITUTE OF MEDICAL BIOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGEInventors: Yunzhang Hu, Ningzhu Hu, Haixuan Wang
-
Publication number: 20130190345Abstract: The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS.Type: ApplicationFiled: April 29, 2011Publication date: July 25, 2013Applicants: CSPC Zongqi Pharmaceutical Technology (Shijiahuang) Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical SciencesInventors: Jiandong Jiang, Danqing Song, Nana Du, Zonggen Peng, Yuping Wang, Limei Gao, Yanxing Han, Xin Li, Chunxin Li
-
Publication number: 20130150335Abstract: A paclitaxel/steroid complex comprising paclitaxel and steroid is disclosed. The molar ratio of paclitaxel to steroid is 1:0.2˜4, preferably 1:0.25˜2. A process for the preparation thereof and the use thereof in the manufacture of submicron emulsion, dry emulsion, self-microemulsifying system are also disclosed.Type: ApplicationFiled: October 28, 2010Publication date: June 13, 2013Applicant: Institute of Mataria Medica, Chinese Academy of Medical SciencesInventors: Yuling Liu, Xuejun Xia, Ruifang Guo, Pengxiao Zhang, Cuiping Zhou, Renyun Wang, Dujia Jin